Asset
SERALUTINIB
Gossamer Bio Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03926793 | phase1 | completed | 2020-02-04 | 2021-05-05 | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension |
| NCT04456998 | phase2 | completed | 2020-11-12 | 2022-10-17 | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) |
| NCT04816604 | phase2 | active_not_recruiting | 2021-04-05 | 2027-12-01 | Gossamer Bio USA, Inc. | Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) |
| NCT03473236 | phase1 | completed | 2017-09-06 | 2018-12-03 | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Phase 1A Safety Trial of Inhaled PK10571 (GB002) |
FDA applications (0)
This company has no applications containing this asset.